Shingo Iwamoto appointed country head for Sandoz in Japan
Shingo Iwamoto will also oversee Japanese business of Aspen Global Incorporated (AGI), successfully acquired by Sandoz on February 1 this year
Japan, world’s third largest generics and off-patent market, is central to Sandoz global strategy
Tokyo, March 25, 2020– Sandoz announced today that Shingo Iwamoto, currently President and representative director of Aspen Japan, has been appointed Country Head for Sandoz in Japan with effect from April 1, 2020. He will report to Francisco (Paco) Ballester, Head, Sandoz International Region.
Paco Ballester said: “I am pleased that Iwamoto-san has agreed to take on this important role as we accelerate our integration of Sandoz and Aspen Japan K.K. His strong track record in commercial excellence, focus on people and culture, and commitment to patients and customers will be key to strengthening our position in Japan, the world’s third largest market for generics and off-patent medicines. I look forward to his collaborative leadership and strong market focus on driving access to help meet patient and customer needs, and to take Sandoz to the next level in Japan.”
Shingo Iwamoto said: “I am grateful and honored for the opportunity to represent Sandoz in Japan as well as to continue to represent Aspen Japan K.K. I am looking forward to using my experience in the pharmaceutical market to grow the Sandoz K.K. business and further develop the lasting bonds we have with patients and customers.”
Shingo has been running the Japanese business of Aspen Global Incorporated (AGI) since 2016, and successfully delivered on sales and profits targets for three consecutive years. He also brings with him over 36 years of experience in the pharmaceutical industry, particularly in the areas of strategy, sales and marketing.
Prior to Aspen, Shingo held a variety of other leadership positions at Teva Seiyaku and Astellas Pharma, including Managing Director for the Sales and Marketing Department at Teva Seiyaku, and responsibility for the Southeast Asia and Oceania business of Astellas Pharma.
Shingo is a Japanese national and graduated with a Biochemistry degree from Meiji University.
Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as “potential,” “can,” “will,” “plan,” “expect,” “anticipate,” “look forward,” “believe,” “committed,” “investigational,” “pipeline,” “launch,” or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Neither can there be any guarantee that, if approved, such generic or biosimilar products will be approved for all indications included in the reference product’s label. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; the particular prescribing preferences of physicians and patients; competition in general, including potential approval of additional generic or biosimilar versions of such products; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; litigation outcomes, including intellectual property disputes or other legal efforts to prevent or limit Sandoz from selling its products; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG’s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Sandoz Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars. Our purpose is to pioneer access for patients by developing and commercializing novel, affordable approaches that address unmet medical need. Our ambition is to be the world’s leading and most valued generics company. Our broad portfolio of high-quality medicines, covering all major therapeutic areas, accounted for 2019 sales of USD 9.7 billion. Sandoz is headquartered in Holzkirchen, in Germany's Greater Munich area.